Poxel S.A.
POXEL.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.75M
Close$
Share Statistics
| Market cap | $7.75 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.38 |
| Beta | 1.28 |
| Outstanding Shares | 51,434,263 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.35 |
|---|---|
| PEG | -0.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 24, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Poxel S.A.
5 employees
CEO: Yves Decadt Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Im...